Sales & Marketing News | pharmaphorum

News

Orchard’s MLD gene therapy becomes costliest US medicine

Orchard Therapeutics has revealed its US pricing plans for Lenmeldy, its gene therapy for metachromatic leukodystrophy (MLD), placing a $4.25 million price tag on the one-

News

Lonza adds biologics capacity with $1.2bn Roche deal

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part o

News

Iclusig gets FDA nod as frontline therapy for rare leukaemia

Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le

News

EU pharma legislation reforms inch closer to fruition

A key hurdle in front of the EU reforms to pharma legislation has fallen, after the European Parliament’s Environment, Public Health and Food Safety (ENVI) committee appro

News

BMS completes $14bn takeover of Karuna

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha

News

Havas Lynx takes three Golds at PM Society Awards 2024

The PM Society’s 38th annual awards were held last week, on Friday 15th March, at the JW Marriott Grosvenor House London, at which over 900 industry professionals came tog

Orchard’s MLD gene therapy becomes costliest US medicine

Lonza adds biologics capacity with $1.2bn Roche deal

Iclusig gets FDA nod as frontline therapy for rare leukaemia

EU pharma legislation reforms inch closer to fruition

BMS completes $14bn takeover of Karuna

Havas Lynx takes three Golds at PM Society Awards 2024

Activist investor renews its criticism of Novavax

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks